Your Weekly Pharma Scoop: Valeant’s CRL Resolution, Eagle Undervalued, Array Positive Results
- This is the once-weekly Pharma scoop published by the Total Pharma Tracker.
- In today's analysis, Valeant's CRL issue may be resolved soon.
- Array BioPharma showed positive results in phase 3 trials.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is starting a weekly scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks. The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data (not shown here), abstract selections, AdComm coverages, Buy/Sell summaries (not shown here) etc are also available to subscribers only. However, today, some of these sections are shown here to all so you get an idea of the kind of data and analysis that will be made available to subscribers. From next week, only an abridged version of this material will be available to non-subscribers.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.